ARS Pharmaceuticals, Inc.
SPRY
$9.72
-$0.08-0.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -32.24% | -167.97% | 361.05% | -52.83% | -21.61% |
| Total Depreciation and Amortization | -0.36% | 865.52% | 38.10% | 16.67% | 63.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 81.72% | 22.73% | 54.05% | 20.81% | 9.44% |
| Change in Net Operating Assets | 89.90% | 2.43% | -471.41% | -23.50% | 68.07% |
| Cash from Operations | 2.82% | -197.00% | 390.34% | -98.75% | -8.48% |
| Capital Expenditure | 43.96% | 69.87% | -115.71% | -268.42% | 54.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 66.77% | 128.74% | -698.29% | 234.50% | -49.56% |
| Cash from Investing | 67.12% | 128.56% | -705.07% | 232.99% | -48.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 272.00% | -52.71% | 125.44% | 24.77% | 111.24% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 272.00% | -98.98% | 10,328.82% | 24.77% | 111.24% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 206.60% | -198.15% | 268.20% | 115.64% | -29.50% |